[Use of magnesium sulfate in obstetrics]

Gynecol Obstet Fertil. 2012 Oct;40(10):605-13. doi: 10.1016/j.gyobfe.2012.08.005. Epub 2012 Sep 18.
[Article in French]

Abstract

Magnesium sulfate (MgSO(4)) is the best treatment of eclampsia, reduces the risk of recurrence better than other anticonvulsants and is recommended as first line in cases of eclampsia. In cases of severe pre-eclampsia and especially when prodromes are present, MgSO(4) reduces better than conventional anticonvulsants the risk of eclampsia. More recently, MgSO(4) was used in cases of preterm delivery to reduce the risk of cerebral palsy in premature infants. Three large randomized trials have obtained convergent results which all tended to show a neuroprotective effect of MgSO(4). These trials were included in three meta-analyzes that showed a 30% reduction in the incidence of cerebral palsy before 32 weeks gestation suggesting that this drug should be used in cases of preterm birth. A protocol using low doses associated with a well-conducted maternal surveillance reduces of maternal hypermagnesemia and the risk of maternal toxicity.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Cerebral Palsy / prevention & control
  • Eclampsia / drug therapy
  • Female
  • Humans
  • Infant, Newborn
  • Infant, Premature, Diseases / prevention & control
  • Magnesium Sulfate / therapeutic use*
  • Neuroprotective Agents
  • Obstetric Labor, Premature / drug therapy
  • Pre-Eclampsia / drug therapy
  • Pregnancy
  • Pregnancy Complications / drug therapy*
  • Randomized Controlled Trials as Topic

Substances

  • Neuroprotective Agents
  • Magnesium Sulfate